Adam B. Weiner, Urologist at Cedars Sinai Medical Center, shared a post on X:
“Tansdermal Estradiol (tE2) vs ADT for locally advanced prostate cancer.
NEJM – New phase 3 RCT (PATCH/STAMPEDE-1)
tE2 patches are noninferior to LHRH agonists for metastasis-free survival (n=1,360)
- 87.1% vs 85.9% 3-yr MFS
- Way fewer hot flashes (44% vs 89%)
- Lower fracture rates
- More gynecomastia
Same cancer control. Better side effect profile. Patient-applied. Cheaper.
Time to rethink ADT?
Title: Transdermal Estradiol Patches in Locally Advanced Prostate Cancer
Authores: Ruth E. Langley, Duncan C. Gilbert, Stephen Mangar, Stuart Rosen, Ellie Bourmaki, Hannah L. Rush, Subramaniam Kananga Sundaram, Abdulla Alhasso, Roger Kockelbergh, Hoda Abdel-Aty, Claire L. Amos, Louise Brown, Simon Brown, Charlene Carvalho, Kitty Chan, Gerald Collins, William Cross, John Deighan, Sanjay Dixit, Trinh Duong, James Dyer, Joanna Gale, Silke Gillessen, Anna Griffiths, Marc Laniado, Anna Lydon, Neil McPhail, Archie MacNair, Sanjeev Madaan, John Marshall, David Matheson, Robin Millman, Wael Mohamed, Laura Murphy, Krishna Narahari, Christopher Parker, Miguel Panades, Alvan Pope, Arpita Raval, Angus Robinson, Martin Russell, Christopher Scrase, Matthew Sydes, Rafal Turo, Ram Venkitaraman, Simona Wade, Howard Kynaston, Gerhardt Attard, Nicholas D. James, Noel Clarke, Mahesh K. Parmar, D.Phil., and Matthew Nankivell.

Other articles featuring Adam B. Weiner on OncoDaily.